interferon gamma (IFNG)

Overview

IFNG encodes interferon gamma (IFN-γ), a key pro-inflammatory cytokine produced primarily by activated T cells and natural killer cell. It is a central mediator of type 1 immune responses, promoting macrophage activation, antigen presentation, and cytotoxic immune function. In biomedical research, IFNG is widely used as a marker of Th1- and Tc1-biased immunity and is frequently measured as an indicator of vaccine immunogenicity, anti-tumor immune activation, and inflammatory disease activity.

Although IFNG is not a structural cellular component in the classical sense, it is often studied in cellular and tissue contexts because its expression reflects immune-cell activation states and immune microenvironment remodeling. Its signaling is closely linked to pathways involving STAT1, antigen presentation, checkpoint regulation, and inflammatory cytokine networks, including IL-2, IL-6, IL-17A, TNF-α, and GM-CSF. In recent studies, IFNG has been repeatedly used as a readout for immune stimulation or suppression across infections, cancer, autoimmunity, and vaccine development.

Recent Publications Summary

Recent publications have continued to position interferon gamma (IFNG) as a central inflammatory and immunoregulatory target across diverse disease contexts. In a multi-omics aging analysis, IFNG emerged as one of the most robust pro-aging circulating inflammatory proteins in Mendelian randomization analyses, alongside IL-12B and IL-2, supporting a causal association with biological aging phenotypes 42343471Jun. In melanoma, IFNG was included in an 8-gene immune-related prognostic signature derived from transcriptomic and clinical datasets, indicating its relevance to tumor immune stratification and the immune microenvironment 42216340May. IFNG was also used as an immune marker in colorectal cancer subtype analyses, where its expression was correlated with immune cell fractions and incorporated into multi-omics modeling of immunophenotypes 41872462Mar.

Several studies focused on IFNG-driven signaling pathways and downstream cellular responses. In retinal transplantation models, investigators identified a Th1-skewed, IFNG-rich immune milieu and showed that IFNG-JAK1 signaling promoted an immunogenic state in human embryonic stem-cell-derived retinal pigment epithelium, characterized by increased HLA expression and antigen-presentation features; brief ex vivo ruxolitinib conditioning attenuated this response and improved graft survival and visual outcomes in humanized models 42309064Jun. In granulomatous skin disease, IFNG was described as a central driver of macrophage activation in granuloma annulare and cutaneous sarcoidosis, with IFNG-induced oxidative phosphorylation and a STAT1/ETC/GBP1 response network identified in single-cell and in vitro studies; inhibition of IFNG signaling, electron transport chain complexes, or GBP1 reduced granuloma formation, and metformin suppressed IFNG activation in vitro 42213834May.

IFNG also appeared in studies of immune engineering and therapeutic activation. A compact TnpB-ωRNA genome regulation platform was used to activate CXCL9, IL-15, and IFNG in an AAV-based immunotherapy strategy, enhancing T-cell migration and activation and improving antitumor activity in preclinical models 41917051Mar. In solid tumor cell therapy, an ICAM1-targeting chimeric costimulatory receptor was described as part of a feed-forward loop in which IFNG released during early T-cell engagement upregulated ICAM1, thereby reinforcing tumor recognition and supporting T-cell proliferation, cytokine production, and cytotoxicity 42043451Apr. IFNG was also one of the cytokines profiled in a biomimetic electrochemical biosensing platform designed for multiplexed detection of inflammatory cytokines, where the sensor achieved sensitive and selective IFNG measurement in serum 42384130Jul.

Outside oncology and regenerative medicine, IFNG was linked to infectious disease immunomodulation. In a case series of severe or disseminated coccidioidomycosis, patients with severe disease received recombinant IFNG as adjunctive therapy alongside antifungals, based on intracellular cytokine staining and clinical context; the series reported favorable survival and clinical improvement in many patients 41778809Mar. IFNG was also incorporated into an in silico multi-epitope vaccine design for enterovirus A71, where selected epitopes were predicted to elicit IFNG responses as part of the vaccine’s immunogenic profile 42081143May.

What Changes, What Holds

1. IFNG now looks like a causal contributor to aging-associated inflammation and immune stratification in cancer
REINFORCES Multi-omics aging work strengthens the view of IFNG as a broad inflammatory readout by placing it among circulating proteins linked to biological aging, while the melanoma and colorectal cancer analyses extend its established use as an immune-state marker into prognostic and subtype modeling. These studies do not displace the baseline role of IFNG in type 1 immunity; they sharpen its utility as a biomarker of immune microenvironment state and suggest it may track systemic inflammaging as well as tumor immunity 42343471Jun42216340May.

2. IFNG signaling is being used to explain tissue immunogenicity and granuloma formation, not just immune activation in general
REINFORCES The retinal transplantation and granulomatous skin disease studies fit squarely within the baseline account that IFNG promotes antigen presentation, macrophage activation, and inflammatory remodeling. What changes is the level of mechanistic detail: IFNG-JAK1 signaling is tied to graft immunogenicity, and an IFNG-linked STAT1/ETC/GBP1 program is implicated in granuloma biology. The evidence is still largely preclinical and mechanistic, so it supports pathway-level refinement rather than a new role 42309064Jun42213834May.

3. IFNG is increasingly being engineered as a therapeutic output rather than only measured as a response marker
NEW DIRECTION The immune-engineering and biosensing papers add a use case the Overview does not cover: deliberate activation or multiplexed detection of IFNG in therapeutic platforms. That does not contradict its established biology, but it moves IFNG from passive readout toward an actionable component in immunotherapy design and assay development. The antitumor constructs remain preclinical, so whether IFNG induction is broadly beneficial or context-limited still needs clinical validation 41917051Mar42384130Jul.

4. Recombinant IFNG is being repurposed as adjunctive therapy in severe fungal infection
NEW DIRECTION Adjunctive use in disseminated coccidioidomycosis extends IFNG beyond its baseline role as a marker and mediator of type 1 immunity into direct treatment support for infection. The Overview does not claim this therapeutic role, so this is an added application rather than a contradiction. The evidence is limited to a small clinical series, which is enough to suggest plausibility but not to settle which patients benefit or how durable the effect is 41778809Mar42081143May.

Overview update candidates: IFNG as a causal pro-aging inflammatory protein; IFNG-JAK1 and STAT1/ETC/GBP1 pathway details in graft immunogenicity and granuloma formation; therapeutic engineering/activation of IFNG in immunotherapy platforms; adjunctive recombinant IFNG for severe coccidioidomycosis.